These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

873 related items for PubMed ID: 32796451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.
    Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J.
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
    Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 13. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard.
    Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E.
    J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
    [Abstract] [Full Text] [Related]

  • 14. 68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
    Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
    [Abstract] [Full Text] [Related]

  • 15. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse.
    Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Velikyan I, Sörensen J.
    Sci Rep; 2020 Mar 19; 10(1):4993. PubMed ID: 32193430
    [Abstract] [Full Text] [Related]

  • 16. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I, Golubic AT, Zuvic M, Smitran T, Jukic N, Gamulin M, Kastelan Z, Huic D.
    Nucl Med Rev Cent East Eur; 2024 Mar 19; 27(0):6-12. PubMed ID: 38680016
    [Abstract] [Full Text] [Related]

  • 17. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 18. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.
    Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.
    Eur J Nucl Med Mol Imaging; 2017 Jan 15; 44(1):92-101. PubMed ID: 27557844
    [Abstract] [Full Text] [Related]

  • 19. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
    Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C.
    Nucl Med Commun; 2017 Dec 15; 38(12):1094-1102. PubMed ID: 28957842
    [Abstract] [Full Text] [Related]

  • 20. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.
    Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 15; 45(11):1884-1897. PubMed ID: 29876619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.